Journal for ImmunoTherapy of Cancer View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2013

PUBLISHER

BioMed Central

LANGUAGE

en

HOMEPAGE

http://jitc.biomedcentral.com

Recent publications latest 20 shown

  • 2019-12 Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
  • 2019-12 Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
  • 2019-12 Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
  • 2019-12 Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
  • 2019-12 Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
  • 2019-12 HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
  • 2019-12 The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella
  • 2019-12 NKG2D signaling certifies effector CD8 T cells for memory formation
  • 2019-12 Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
  • 2019-12 Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
  • 2019-12 Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
  • 2019-12 Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence
  • 2019-12 A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
  • 2019-12 A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer
  • 2019-12 Two roads for oncolytic immunotherapy development
  • 2019-12 Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
  • 2019-12 TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
  • 2019-12 Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
  • 2019-12 Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
  • 2019-12 A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "1.241", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "2.798", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "8.374", 
            "type": "Rating"
          }
        ], 
        "description": "

    Journal for ImmunoTherapy of Cancer (JITC) is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.\u00a0 The journal\u2019s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.

    ", "editor": [ { "familyName": "Romero", "givenName": "Pedro", "type": "Person" } ], "id": "sg:journal.1049249", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2051-1426" ], "license": "Fully Open Access", "name": "Journal for ImmunoTherapy of Cancer", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "21100466864" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101620585" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "40425" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2013254548" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "49249" ] } ], "publisher": { "name": "BioMed Central", "type": "Organization" }, "publisherImprint": "BioMed Central", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2013", "type": "Periodical", "url": "http://jitc.biomedcentral.com" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1049249'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1049249'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1049249'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1049249'


     

    This table displays all metadata directly associated to this object as RDF triples.

    78 TRIPLES      21 PREDICATES      30 URIs      24 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1049249 schema:about sg:ontologies/product-market-codes/B14000
    2 sg:ontologies/product-market-codes/H33160
    3 schema:contentRating N28ee86cc29224a1a8a27d9a30259145b
    4 N98add70c067f40feb52ab28a21017bbc
    5 Nb046576a34594ed38dfb891d4776c0ea
    6 schema:description <p><i>Journal for ImmunoTherapy of Cancer (JITC)</i> is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.  The journal’s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.</p>
    7 schema:editor Nebafbc5a03804ca085b8c45ba3d51376
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 2051-1426
    11 schema:license Fully Open Access
    12 schema:name Journal for ImmunoTherapy of Cancer
    13 schema:productId N0993d72362414cbfa8335ffc22680ace
    14 N64e022af81744792a44723b435e5c89b
    15 N78df0595c25f497582ba4732c8d34662
    16 N8d12fe5c68e643b1be64921111427188
    17 N9f7f73cf8e1d4e46a12248a197e62f85
    18 Nd584c7311edf480885f2a2c4df219c5f
    19 schema:publisher N61817e8cc61643df8b40d9acb0c67481
    20 schema:publisherImprint BioMed Central
    21 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249
    22 schema:sdDatePublished 2019-03-18T11:05
    23 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    24 schema:sdPublisher Nfbb92ef36b2145bd87092d13095bd3a7
    25 schema:startYear 2013
    26 schema:url http://jitc.biomedcentral.com
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset journals
    29 rdf:type schema:Periodical
    30 N0993d72362414cbfa8335ffc22680ace schema:name wos_id
    31 schema:value 2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER
    32 rdf:type schema:PropertyValue
    33 N1b4726d07e464b2099ca2214a00147e3 schema:familyName Romero
    34 schema:givenName Pedro
    35 rdf:type schema:Person
    36 N28ee86cc29224a1a8a27d9a30259145b schema:author Nbb74cdc550ee4ee5ab105f7d8185b263
    37 schema:ratingValue 1.241
    38 rdf:type schema:Rating
    39 N61817e8cc61643df8b40d9acb0c67481 schema:name BioMed Central
    40 rdf:type schema:Organization
    41 N64e022af81744792a44723b435e5c89b schema:name nlm_unique_id
    42 schema:value 101620585
    43 rdf:type schema:PropertyValue
    44 N78df0595c25f497582ba4732c8d34662 schema:name springer_id
    45 schema:value 40425
    46 rdf:type schema:PropertyValue
    47 N7b695d38074b4f5fbe94f8cb4f60f5a0 rdf:first sjr
    48 rdf:rest rdf:nil
    49 N8d12fe5c68e643b1be64921111427188 schema:name scopus_id
    50 schema:value 21100466864
    51 rdf:type schema:PropertyValue
    52 N98add70c067f40feb52ab28a21017bbc schema:author N7b695d38074b4f5fbe94f8cb4f60f5a0
    53 schema:ratingValue 2.798
    54 rdf:type schema:Rating
    55 N9f7f73cf8e1d4e46a12248a197e62f85 schema:name dimensions_id
    56 schema:value 49249
    57 rdf:type schema:PropertyValue
    58 Nb046576a34594ed38dfb891d4776c0ea schema:author Ne09f5a4c12d8402eb87d485b628cf239
    59 schema:dateCreated 2017
    60 schema:ratingValue 8.374
    61 rdf:type schema:Rating
    62 Nbb74cdc550ee4ee5ab105f7d8185b263 rdf:first snip
    63 rdf:rest rdf:nil
    64 Nd584c7311edf480885f2a2c4df219c5f schema:name lccn_id
    65 schema:value 2013254548
    66 rdf:type schema:PropertyValue
    67 Ne09f5a4c12d8402eb87d485b628cf239 rdf:first impact_factor_wos
    68 rdf:rest rdf:nil
    69 Nebafbc5a03804ca085b8c45ba3d51376 rdf:first N1b4726d07e464b2099ca2214a00147e3
    70 rdf:rest rdf:nil
    71 Nfbb92ef36b2145bd87092d13095bd3a7 schema:name Springer Nature - SN SciGraph project
    72 rdf:type schema:Organization
    73 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    74 schema:name Immunology
    75 rdf:type schema:DefinedTerm
    76 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    77 schema:name Oncology
    78 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...